Seres Therapeutics, Inc. (MCRB) Dividend History

Seres Therapeutics, Inc. is a biotechnology company focused on developing microbiome-based therapeutics. The company utilizes its proprietary platform to discover, develop, and commercialize biologic products that modulate the human microbiome to treat various diseases, including those related to gastrointestinal health. Founded in 2014 and headquartered in Cambridge, Massachusetts, Seres aims to address unmet medical needs through innovative microbiome science.

200 Sidney Street, Cambridge, MA, 02139
Phone: 617 945 9626
Website: https://www.serestherapeutics.com

Dividend History

Seres Therapeutics, Inc. currently does not pay dividends

Company News

  • Denodo University Challenge Now Open: Data and AI for Real-World Impact

    Denodo, a leader in data management, has announced the Denodo University Challenge, 'Data and AI for Real-World Impact', which aims to encourage students to develop innovative AI-driven solutions that have a demonstrable impact on social and economic challenges. The challenge will leverage Denodo's data management and AI tools, including the Denodo Platform and the Denodo AI SDK.

    GlobeNewswire Inc.
  • Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Morgan Stanley boosted the price target for Sea Limited (NYSE: SE) from $47 to $65. Morgan Stanley analyst Mark Goodridge maintained an Equal-Weight rating. Sea shares gained 3.4% to close at $55.75 on Tuesday. See how other analysts view this stock. Barclays raised the price target for Target Corporation (NYSE: TGT) from $142 to $169. Barclays analyst Seth Sigman maintained an Equal-Weight rating. Target shares jumped 12% to close at $168.58 on Tuesday. See how other analysts view this stock. Chardan Capital lowered Seres Therapeutics, Inc. (NASDAQ: MCRB) price target from $10 to $8. Chardan Capital analyst Keay Nakae maintained a Buy rating. Seres Therapeutics shares fell 7% ...

    Benzinga
    Featured Companies: CHPT COOK CRWD EMR ROST TGT TWLO
  • Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?

    Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

    Zacks Investment Research
    Featured Companies: HALO
  • Seres Therapeutics: Evaluating Vowst's Market Challenges (Rating Downgrade)

    Seres's FDA-approved Vowst faces commercial challenges despite clinical success, impacting financials. Read why I downgrade MCRB stock to a strong sell.

    Seeking Alpha
  • Best Penny Stocks To Buy? 5 With Big News This Week

    Penny stocks to watch with big news this week. The post Best Penny Stocks To Buy? 5 With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    PennyStocks
Page data last updated 07/23/2025 21:33:49 UTC